Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA (opens in a new tab)

news-medical.net · 2026-10-26

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Also referencedpresented as the new finding

    https://www.esmo.org/press-releases/omega-3-epa-linked-to-longer-survival-after-surgery-for-colorectal-cancer-liver-metastases

    Where the story links (opens in a new tab)
The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 5Not checkedPatients assigned to receive high-dose eicosapentaenoic acid (EPA) before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2 trial presented at the ESMO Congress 2026.View evidenceHide evidence

As statedlonger overall survival

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 5Not checkedThe randomized, double-blind, placebo-controlled EMT2 trial enrolled 418 patients scheduled for liver resection with curative intent at 13 UK hepatobiliary surgery centers, and patients received 4 g daily of EPA as high-purity prescription icosapent ethyl or mineral oil placebo.View evidenceHide evidence

As stated418 patients; 4 g daily; 13 UK centers

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 5Not checkedEstimated five-year overall survival was 62.0% with EPA versus 45.1% with placebo, with a hazard ratio for death of 0.68; median overall survival had not been reached with EPA versus 59.0 months with placebo.View evidenceHide evidence

As stated62.0% vs 45.1%; HR 0.68; median not reached vs 59.0 months

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 5Not checkedMedian progression-free survival was similar in the two groups, and EPA was reported to be well tolerated with no excess adverse events, bleeding, atrial fibrillation, or negative impact on quality of life.View evidenceHide evidence

As statedmedian PFS 13.5 vs 12.9 months; HR 0.89

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 5 of 5Not checkedThe article says confirmatory results are likely needed before incorporating EPA into daily clinical practice, and that the survival benefit may reflect effects on the body's response to cancer, including cachexia or immune response.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

CandidateOpen access

Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol.

BMJ Open · 2023 · PubMed, Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

PTH-106 Survival outcomes following hepatectomy for stage iv colorectal liver metastases: a comparison of liver- versus colon-first approach

Liver – Liver Cancer · 2015 · Crossref

Source (opens in a new tab)

Explore all search results